Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Balde
G Bastert

Showing results (221-230 of 232) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study GroupM Schumacher, G Bastert, H Bojar, et al.
Nature Medicine|April 3, 2001
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrowM Feuerer, P Beckhove, L Bai, et al.
Nuklearmedizin. Nuclear Medicine|October 1, 1995
[Immunoscintigraphy of breast cancer xenografts. 99m-Tc-labeled anti-mucin monoclonal antibodies BM-7 and 12H12]T H Brümmendorf, S Kaul, J Schuhmacher, et al.
British Journal of Cancer|January 1, 1997
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancerE F Solomayer, I J Diel, D Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II studyA Schneeweiss, J Huober, H-P Sinn, et al.
International Journal of Oncology|September 18, 2004
Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogensC Coutelle, B Höhn, M Benesova, et al.
Stem Cells (Dayton, Ohio)|March 10, 2001
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancerA Schneeweiss, M Hensel, R Goerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasisI J Diel, E F Solomayer, M J Seibel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapyA Schneeweiss, I Diel, M Hensel, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Pageof 24

Showing results (221-230 of 232) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study GroupM Schumacher, G Bastert, H Bojar, et al.
Nature Medicine|April 3, 2001
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrowM Feuerer, P Beckhove, L Bai, et al.
Nuklearmedizin. Nuclear Medicine|October 1, 1995
[Immunoscintigraphy of breast cancer xenografts. 99m-Tc-labeled anti-mucin monoclonal antibodies BM-7 and 12H12]T H Brümmendorf, S Kaul, J Schuhmacher, et al.
British Journal of Cancer|January 1, 1997
Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancerE F Solomayer, I J Diel, D Wallwiener, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II studyA Schneeweiss, J Huober, H-P Sinn, et al.
International Journal of Oncology|September 18, 2004
Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogensC Coutelle, B Höhn, M Benesova, et al.
Stem Cells (Dayton, Ohio)|March 10, 2001
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancerA Schneeweiss, M Hensel, R Goerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasisI J Diel, E F Solomayer, M J Seibel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapyA Schneeweiss, I Diel, M Hensel, et al.
British Journal of Cancer|April 3, 1999
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancerS Hohaus, L Funk, S Martin, et al.
Pageof 24